January 26th 2023
The report also suggests that ataxia telangiectasia and Rad3-related protein inhibition could be a valuable tool to overcome resistance.
FDA Approves Darolutamide Combo for Metastatic Hormone-Sensitive Prostate Cancer
August 9th 2022Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.
Read More
Dr Ashley Ross on the Potential for Targeted Therapies Earlier in Prostate Cancer Treatment
February 3rd 2021Ashley Ross, MD, urologist and associate professor at the Northwestern University Feinberg School of Medicine, gives insight on the potential for PARP inhibitors in earlier disease settings for prostate cancer.
Read More
Study Finds Shorter Radiation Regimen Safe, Effective for Advanced Prostate Cancer
January 30th 2021Shortening a traditional 45-day course of radiation therapy to 5 days of stereotactic body radiotherapy for patients with advanced, high-risk prostate cancer is safe and effective, a study from UCLA Jonsson Comprehensive Cancer Center found.
Read More
Congress passes legislation that will delay the start of the Radiation Oncology (RO) Advanced Payment Model; examining the newly identified variant of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19); a study finds Hispanics and those without college degrees most subject to excess death during pandemic.
Read More
African American Men Face Higher Risk of Aggressive Prostate Cancer, but Not Necessarily Death
November 26th 2020Multiple studies have suggested African American men tend to have more aggressive forms of prostate cancer, but a new study suggests that may not translate to a higher risk of death.
Read More